<DOC>
	<DOCNO>NCT00393861</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness oxaliplatin bevacizumab patient refractory relapse germ cell tumor .</brief_summary>
	<brief_title>Study Oxaliplatin Plus Bevacizumab Germ Cell Tumor Patients</brief_title>
	<detailed_description>This study propose look establish combination oxaliplatin bevacizumab use colorectal cancer refractory germ cell tumor patient . Oxaliplatin drug know activity . Although bevacizumab single agent data , combine dramatically well numerous chemotherapy drug , oxaliplatin increase response rate improve survival . Furthermore , VEG-F appear important target germ cell tumor many type solid tumor . We use identical dosage oxaliplatin + bevacizumab utilize previously treat colorectal cancer , without addition 5-FU + leucovorin . This dose schedule proven safe effective .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histological serologic proof metastatic germ cell neoplasm ( gonadal extragonadal primary ) . Patients seminoma nonseminoma eligible , woman ovarian germ cell tumor . Patient 's disease must amenable cure either surgery chemotherapy opinion investigator . Patients must fail initial cisplatin combination chemotherapy administer curative intent BEP , EP , VIP , similar regimen . Patients fail demonstrated progressive disease high dose chemotherapy carboplatin etoposide . ( With exception late relapse primary mediastinal nonseminomatous germ cell tumor . Patients late relapse primary mediastinal nonseminomatous germ cell tumor must fail least 1 salvage chemotherapy regimen . Patients must prior exposure paclitaxel , gemcitabine , combination paclitaxel + gemcitabine . Patients must adequate hematologic function ( WBC &gt; 4,000/mm3 platelet &gt; 100,000/mm3 ) obtain &lt; 4 week prior registration . Patients must adequate hepatocellular function ( SGOT &lt; 4 x normal Bilirubin &lt; 2.0 mg/dl ) obtain &lt; 4 week protocol registration . Serum Creatinine must &lt; 2.0 mg/dl obtain &lt; 4 week protocol registration . Patients must ECOG performance status 0 , 1 , 2 . Patients must least 28 day post major surgery , open biopsy , significant traumatic injury time study registration . Patients must least 7 day post minor surgical procedure , exclude placement vascular access device time study registration . Patients must least 18 year old time consent . Patients active , unresolved infection and/or receive concurrent treatment parenteral antibiotic ineligible . Patients eligible antibiotic discontinue least 7 day . Patients may significant bleeding . Patients INR &gt; 1.5 eligible unless patient anticoagulant therapeutic INR 1.5 3 . Patients coumadin eligible unless low dose coumadin keep vascular access device patent . Patients history arterial thromboses , unstable angina , transient ischemic attach ( TIA ) , cerebral vascular accident ( CVA ) , myocardial infarction within last 6 month eligible . Patients must know CNS metastasis . A Head CT MRI perform clinically indicate . Patients must receive radiotherapy chemotherapy within 28 day prior study registration , recover toxicity prior treatment . Patients must prior history hypertensive crisis hypertensive encephalopathy . Patients must New York Heart Association ( NYHA ) Grade II great congestive heart failure . Patients must history significant vascular disease . Patients must evidence bleed diathesis coagulopathy . Patients must inadequately control hypertension ( define systolic blood pressure 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . Patients must history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study registration . Patients must serious , nonhealing would , ulcer bone fracture . Patients must proteinuria screen demonstrated urine protein : Creatinine ( UPC ) ratio â‰¥ 1.0 . Patients must know sensitivity component bevacizumab . Patients must pregnant lactating . Patients must grade 3 4 neuropathy . Females child bear potential must pregnant . A negative pregnancy test require within 7 day prior begin treatment . NOTE THE FOLLOWING GUIDELINES FOR USE IN THIS PROTOCOL : Progressive metastatic disease document appearance metastatic lesion PA lateral chest xray , C.T . scan , image study , presence rise serum HCG AFP . If rise serum marker evidence progressive disease , least 2 consecutive determination must do exhibit serologic progression alternative cause increase serum level substance must present [ cross reaction LH ( test necessary testosterone suppression LH ) , ingestion marijuana , hepatitis , etc. ] . Patients consider fail prior regimen fail obtain complete response per RECIST outline section 6 . Patients clinical situation grow teratoma ( normal decline marker radiographic clinical progression ) consider surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Germ Cell Tumor</keyword>
	<keyword>Germ Cell Cancer</keyword>
</DOC>